Transcriptomic Signature of Painful Human Neurofibromatosis Type 2 Schwannomas

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2021 May 30

PMID 34053190

Citations 2

Authors

Phanidhar Kukutla

Sherif G Ahmed

Daniel M Dubreuil

Ahmed Abdelnabi

Murat Cetinbas

Giulia Fulci

Berent Aldikacti

Anat Stemmer-Rachamimov

Scott R Plotkin

Brian Wainger

Ruslan I Sadreyev

Gary J Brenner

Affiliations

Soon will be listed here.

Abstract

Schwannomas are benign neoplasms that can cause gain- and loss-of-function neurological phenotypes, including severe, intractable pain. To investigate the molecular mechanisms underlying schwannoma-associated pain we compared the RNA sequencing profile of painful and non-painful schwannomas from NF2 patients. Distinct segregation of painful and non-painful tumors by gene expression patterns was observed. Differential expression analysis showed the upregulation of fibroblast growth factor 7 (FGF7) in painful schwannomas. Behavioral support for this finding was observed using a xenograft human NF2-schwannoma model in nude mice. In this model, over-expression of FGF7 in intra-sciatically implanted NF2 tumor cells generated pain behavior compared with controls.

Citing Articles

Optimal Delivery of Pain Management in Schwannomatosis: A Literature Review.

Hino U, Tamura R, Toda M Ther Clin Risk Manag. 2025; 21():61-68.

PMID: 39839825 PMC: 11748755. DOI: 10.2147/TCRM.S362794.

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.

Xu D, Yin S, Shu Y NPJ Precis Oncol. 2024; 8(1):133.

PMID: 38879686 PMC: 11180135. DOI: 10.1038/s41698-024-00627-5.

Comparative Transcriptomic Analysis of Archival Human Vestibular Schwannoma Tissue from Patients with and without Tinnitus.

Bommakanti K, Seist R, Kukutla P, Cetinbas M, Batts S, Sadreyev R J Clin Med. 2023; 12(7).

PMID: 37048724 PMC: 10095534. DOI: 10.3390/jcm12072642.

References

Merker V, Esparza S, Smith M, Stemmer-Rachamimov A, Plotkin S . Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22. PMC: 3481897. DOI: 10.1634/theoncologist.2012-0162. View

Prabhakar S, Taherian M, Gianni D, Conlon T, Fulci G, Brockmann J . Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther. 2012; 24(2):152-62. PMC: 3581065. DOI: 10.1089/hum.2012.094. View

Grothe C, Nikkhah G . The role of basic fibroblast growth factor in peripheral nerve regeneration. Anat Embryol (Berl). 2001; 204(3):171-7. DOI: 10.1007/s004290100205. View

Bakker A, La Rosa S, Sherman L, Knight P, Lee H, Pancza P . Neurofibromatosis as a gateway to better treatment for a variety of malignancies. Prog Neurobiol. 2016; 152:149-165. DOI: 10.1016/j.pneurobio.2016.01.004. View

Hargreaves K, Dubner R, Brown F, Flores C, Joris J . A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988; 32(1):77-88. DOI: 10.1016/0304-3959(88)90026-7. View

Jordan J, Smith M, Walker J, Erdin S, Talkowski M, Merker V . Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018; 97(5):e9717. PMC: 5805424. DOI: 10.1097/MD.0000000000009717. View

Evans D . Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009; 4:16. PMC: 2708144. DOI: 10.1186/1750-1172-4-16. View

Arguis M, Perez J, Martinez G, Ubre M, Gomar C . Contralateral neuropathic pain following a surgical model of unilateral nerve injury in rats. Reg Anesth Pain Med. 2008; 33(3):211-6. DOI: 10.1016/j.rapm.2007.12.003. View

Li P, Zhao F, Zhang J, Wang Z, Wang X, Wang B . Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. J Neurosurg Spine. 2015; 24(1):145-54. DOI: 10.3171/2015.3.SPINE141145. View

10.

Merker V, Bredella M, Cai W, Kassarjian A, Harris G, Muzikansky A . Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014; 164A(6):1431-7. DOI: 10.1002/ajmg.a.36466. View

11.

Saydam O, Ozdener G, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov A . A novel imaging-compatible sciatic nerve schwannoma model. J Neurosci Methods. 2010; 195(1):75-7. PMC: 3032262. DOI: 10.1016/j.jneumeth.2010.10.021. View

12.

Ornitz D, Itoh N . The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66. PMC: 4393358. DOI: 10.1002/wdev.176. View

13.

Hucho T, Levine J . Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron. 2007; 55(3):365-76. DOI: 10.1016/j.neuron.2007.07.008. View

14.

Wagner R, Myers R . Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience. 1996; 73(3):625-9. DOI: 10.1016/0306-4522(96)00127-3. View

15.

Schulz A, Grafe P, Hagel C, Baumer P, Morrison H, Mautner V . Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities. Exp Neurol. 2017; 299(Pt B):334-344. DOI: 10.1016/j.expneurol.2017.06.006. View

16.

Liu H, Wu Q, Li J, Liu X, Li K, Zhong Y . Fibroblast growth factor 7 is a nociceptive modulator secreted via large dense-core vesicles. J Mol Cell Biol. 2015; 7(5):466-75. DOI: 10.1093/jmcb/mjv019. View

17.

Furusho M, Dupree J, Bryant M, Bansal R . Disruption of fibroblast growth factor receptor signaling in nonmyelinating Schwann cells causes sensory axonal neuropathy and impairment of thermal pain sensitivity. J Neurosci. 2009; 29(6):1608-14. PMC: 2659639. DOI: 10.1523/JNEUROSCI.5615-08.2009. View

18.

Ji R, Chamessian A, Zhang Y . Pain regulation by non-neuronal cells and inflammation. Science. 2016; 354(6312):572-577. PMC: 5488328. DOI: 10.1126/science.aaf8924. View